Selected Publications

1.           Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma. Cancer Cell. 2024 Oct 23: S1535-6108(24)00366-0. doi: 10.1016/j.ccell.2024.10.003. Online ahead of print. PMID: 39454577.

 

2.           Pascual-Pasto G, McIntyre B, Hines MG, Giudice AM, Garcia-Gerique L, Hoffmann J, Mishra P, Matlaga S, Lombardi S, Shraim R, Schürch PM, Yarmarkovich M, Hofmann TJ, Alikarami F, Martinez D, Tsang M, Gil-de-Gómez L, Spear TT, Bernt K, Wolpaw AJ, Dimitrov DD, Li W, Bosse KR. CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma. Nature Communications. 2024; 15: 7141. Published online 2024 Aug 21. PMID: 39164224. PMCID: PMC11336212.

 

3.           Pascual-Pasto G, McIntyre B, Giudice AM, Alikarami F, Morrissey A, Matlaga S, Hofmann TJ, Burgueño V, Harvey K, Martinez D, Shah AC, Foster JB, Pogoriler J, Eagle RC, Carcaboso AM, Shields CL, Leahey AM, Bosse KR. Targeting GPC2 on intraocular and CNS metastatic retinoblastomas with local and systemic delivery of CAR T-cells. Clinical Cancer Research. 2024; 30 (16): 3578-91. PMID: 38864848. PMCID: PMC11326963.

 

4.           Strijker JGM*, Pascual-Pasto G*, Kalmeijer YJ, Kalaitsidou E, Zhao C, McIntyre B, Matlaga S, Visser LL, Barisa M, Himsworth C, Shah R, Muller H, Schild LG, Hains PG, Zhong Q, Reddel R, Robinson PJ, Catena X, Soengas MS, Margaritis T, Dekker FJ, Anderson J, Molenaar JJ, Bosse KR*, Wu W*, Wienke J*. Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma. bioRxiv. 2024.04.05.588098; doi: https://doi.org/10.1101/2024.04.05.588098

*, these authors contributed equally.

 

5.           Randall MP, Egolf LE, Vaksman Z, Samanta M, Tsang M, Groff D, Evans JP, Rokita JL, Layeghifard M, Shlien A, Maris JM, Diskin SJ, Bosse KR. BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma. Journal of the National Cancer Institute. 2024; 1:138-148. PMID: 37688570. PMCID: PMC9915690.

 

6.           Kim J, Vaksman Z, Egolf LE, Kaufman R, Evans JP, Conkrite KL, Danesh A, Lopez G, Randall MP, Dent MH, Farra LM, Menghani N, Dymek M, Desai H, Hausler R, Penn Medicine BioBank, Regeneron Genetics Center, Cancer Genomics Research Laboratory, Auvil JG, Gerhard DS, Hakonarson H, Maxwell KN, Cole KA, Pugh TJ, Bosse KR, Khan J, Wei JS, Maris JM, Stewart DR, Diskin SJ. Germline pathogenic variants in 786 neuroblastoma patients. Journal of the National Cancer Institute. 2024; 1:149-159. PMID: 37688579. PMCID: PMC9901064.

 

7.           Yarmarkovich M, Marshall QF, Warrington J, Premaratne R, Farrel A, Groff D, Li W, Marco M, Runbeck E, Truong H, Toor JS, Tripathi S, Nguyen S, Shen H, Noel T, Church NL, Weiner AM, Kendsersky N, Martinez D, Weisberg R, Christie M, Eisenlohr L, Bosse KR, Dimitrov DS, Stevanovic S, Sgourakis NG, Kiefel BR, Maris JM. Targeting of intracellular oncoproteins with peptide-centric CARs. Nature. 2023; 623: 820-827. PMID: 37938771. PMCID: PMC10665195.

 

8.           Zhang H-F, Delaidelli A, Javed S, Turgu B, Morrison T, Hughes CS, Yang X, Pachva M, Lizardo MM, Martinez D, Hoffmann J, Shraim S, Huang YZ, Kung SHY, Morin GB, Maris JM, Bosse KR, Williams KC, Sorensen PH. A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma. Science Advances. 2023; 9 (34): eadg669. DOI: 10.1126/sciadv.adg6693. PMID: 37611092 PMCID: PMC10446492.

 

9.           Pascual-Pasto G, McIntyre B, Shraim R, Buongervino SN, Erbe AK, Zhelev DV, Sadirova S, Giudice AM, Martinez D, Garcia-Gerique L, Dimitrov DS, Sondel PM, Bosse KR. A GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies. Journal for ImmunoTherapy of Cancer. 2022; 10 (12): e004704. PMID: 36460335. PMCID: PMC9723962.

 

10.         Bosse KR, Giudice AM, Lane MV, McIntyre B, Schurch PM, Pascual-Pasto G, Buongervino S, Suresh S, Fitzsimmons A, Hyman A, Gemino-Borromeo M, Saggio J, Berko E, Daniels A, Stundon J, Friedrichsen M, Liu X, Margolis M, Li MM, Tierno M, Oxnard G, Maris J, Mosse YP. Serial profiling of circulating tumor DNA identifies dynamic and clinically actionable genomic alterations in high-risk neuroblastoma. Cancer Discovery. 2022; Sep 15. Doi: 10.1158/2159-8290.CD-22-0287. Online ahead of print. PMID: 36108156. PMCID: PMC9722579.

 

11.         Foster JB, Griffin C, Rokita JL, Stern A, Brimley C, Rathi K, Lane MV, Buongervino SN, Smith T, Madsen PJ, Martinez D, Wechsler-Reya RJ, Karikó K, Storm PB, Barrett DM, Resnick AC, Maris JM, Bosse KR. Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors. Journal for ImmunoTherapy of Cancer. 2022; 10 (9): e004450. PMID: 36167467. PMCID: PMC9516314.

 

12.         Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, Volgina D, Pascual-Pasto G, Rodriguez-Garcia A, Uzun Y, Arsenian-Henriksson M, Powell DJ Jr, Bosse KR, Kossenkov A, Tan K, Hogarty MD, Maris JM, Dang CV. Epigenetic state determines inflammatory sensing in neuroblastoma. PNAS. 2022; 119 (6): e2102358119. PMID: 35121657. PMCID: PMC8832972.

 

13.         Heitzeneder S, Bosse KR, Zhongyu Z, Zhelev D, Dhingra S, Majzner RG, Sotillo E, Buongervino S, Xu P, Huang J, Salzer B, Delaidelli A, Bornheimer S, Sahaf B, Alag A, Fetahu I, Hasselblatt M, Parker K, Anbunathan H, Hwang J, Huang M, Klysz DD, Theruvath JL, Vilches-Moure JG, Satpathy AT, Lehner M, Taschner-Mandl S, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity. Cancer Cell. 2022; 40 (1): 53-69. PMID: 34971569.

 

14.         Raman S, Buongervino SN, Lane M, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien J-P, Bosse KR. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational GPC2 epitope. Cell Reports Medicine. 2021; 2 (7): 100344. PMID: 34337560. PMCID: PMC8324494.

 

15.         Buongervino S, Lane M, Garrigan E; Zhelev DV, Dimitrov DS, Bosse KR. Antibody-drug conjugate efficacy in neuroblastoma – role of payload, resistance mechanisms, target density, and antibody internalization. Molecular Cancer Therapeutics. 2021; 20: 2228-39. PMID: 34465595. PMCID: PMC8666002.

 

16.         Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NK, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM. Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma. Cancer Cell. 2017; 32 (3): 295-309.